Immunologic alterations and active aspecific immunotherapy in lung cancer patients.
An immunologic study was undertaken on 89 lung cancer patients and on the basis of results obtained so far, a protocol of active, aspecific immunotherapy by living bacterial vaccines (BCG) and/or synthetic immunopotentiator (methisoprinol) was carried out. First results obtained in patients undergoing immunostimulation are reported together with the observation that while positive humoral effects seem present in stage I and II patients, in cases of spread of the disease results are substantially negative.
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007167:Immunotherapy; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000628:therapy*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D012397:Rosette Formation
D001500:BCG Vaccine; D007136:Immunoglobulins; D007288:Inosine; D007542:Inosine Pranobex